Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 678 results for "Tecfidera"

Can Biogen Idec Take Wing With Tecfidera?

Summary Biogen reported strong Q2 results and raised guidance. Tecfidera for multiple sclerosis was the key growth driver in the quarter. Using reasonable EPS growth estimates, Biogen looks attractive for longer-term investors. Biogen Idec ... Seeking Alpha, 4 hours ago

43 images for Tecfidera

Motley Fool, 6 days ago, 4 days ago
ABC News 4 Charleston, 1 week ago
Pharma Letter, 2 weeks ago
Market Pulse Navigator, 1 month ago
I Stock Analyst, 1 month ago
ABC News 4 Charleston, 1 month ago
Scottrade, 1 month ago
KSWT13, 1 month ago
Global News Canada, 2 months ago
Motley Fool

Biogen Stock's Tecfidera Embarrasses Wall Street

It's hard to imagine that Biogen Idec (NASDAQ: BIIB Tecfidera was the third oral MS drug to get the FDA green-light when it was approved in March 2013, but while Novartis (NYSE: NVS Another great quarter Biogen's second quarter sales jumped 40% ...
 Motley Fool6 days ago NICE Gives Nod to Biogen Idec's MS Drug Tecfidera  FDA News1 week ago MS Drug Tecfidera More Trouble Than It's Worth?  EMax Health1 month ago Gastro Effects Dog Oral MS Drug Tecfidera  MedPage Today1 month ago
American Banking News

Why Biogen Idec Stock Is Firing on All Cylinders

Biogen Idec 's ( NASDAQ: BIIB ) latest earnings report is the envy of the industry as Tecfidera keeps marching toward its multi-billion dollar potential. Beyond multiple sclerosis collaboration revenue from Roche 's best-selling cancer therapy ...
 Motley Fool5 days ago Biogen Idec Second Quarter 2014 Revenues Increase 40% to $2.4 Billion; Company Raises Financial Guidance for the Year  Business Wire6 days ago Biogen Idec Inc ( BIIB )  Stock Junction6 days ago Biogen Idec : Second Quarter 2014 Revenues Increase 40% to $2.4 Billion; Company Raises Financial Guidance for the Year  4 Traders6 days ago

Biogen Trounces Q2 Estimates As Tecfidera Outperforms

Big-cap biotech Biogen Idec (NASDAQ: BIIB ) soundly beat analysts' Q2 expectations and substantially raised its guidance early Wednesday, sending shares up more than 11% in midday trading in the stock market today to near 338, a four-month high. ...
 Investor's Business Daily6 days ago Video: Biogen Trounces Q2 Estimates On Tecfidera  Investor's Business Daily6 days ago

Biogen's Q2 Earnings Surpass Expectations, Tecfidera Shines

Biogen Idec (BIIB) reported second quarter 2014 earnings per share of $3.48 (including the impact of stock-based compensation expense), way above the Zacks Consensus Estimate of $2.80 and the year-ago earnings of $2.29 per share. While oral ...
 Yahoo! Finance6 days ago

Biogen Beats Quarterly Analyst Estimates with New Drug Sales

Biogen Idec Inc. (BIIB) , maker of multiple sclerosis drugs Avonex, Tysabri and Tecfidera, beat analyst estimates with better than expected sales of Tecfidera and new hemophilia drug Alprolix. The company raised its 2014 forecast. Net income for ...
 Bloomberg6 days ago Pop some corks, Tecfidera sales folks: Your $700M for Q2 trounced estimates  FiercePharma6 days ago

Could This 1 Lawsuit Destroy Biogen Idec Stock?

Source: Biogen IDEC. Biogen 's ( NASDAQ: BIIB ) Tecfidera launched a year ago, and it has already become a blockbuster likely to notch more than $2 billion in sales this year. Much of Tecfidera's success is coming at the expense of recently ...
 Motley Fool1 week ago

Biogen Idec Canada Release: British Columbia To Reimburse TECFIDERA???, A First-Line Oral Treatment For Multiple Sclerosis

 BioSpace1 month ago British Columbia to Reimburse TECFIDERA, a First-Line Oral Treatment for Multiple Sclerosis  CEOWorld Magazine1 month ago Biogen reports British Columbia to Reimburse TECFIDERA  Yahoo! Finance1 month ago MS Awareness Month Brings Good News for Ontarians: Province to Reimburse TECFIDERA, a First-Line Oral Treatment for Multiple Sclerosis  Canada NewsWire2 months ago

Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted

BURLINGTON, Mass. , July 22,2014 /PRNewswire/ --Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing ...
 OSIX News1 week ago One Year Post-Launch, All Surveyed U.S. Neurologists Report Having Clinical Experience with Biogen Idec's Tecfidera for the Treatment of Multiple Sclerosis  Vision Monday1 month ago UPDATE: Morgan Stanley Reiterates On Biogen Idec As Positive RPC1063 Data Poses Threat To Tecfidera  Benzinga.com1 month ago Statins for Secondary Progressive Multiple Sclerosis  Sermo.com1 month ago

Biogen Idec lifts annual guidance as Q2 profit, sales jump, boosted by Tecfidera

Biogen Idec announced Wednesday that second-quarter net income jumped 46 percent versus the year-ago period to $715 million, lifted by the rollout of Tecfidera. Sales in the quarter surged 40 percent to $2.4 billion, with Tecfidera posting revenue ...
 FirstWord Pharma6 days ago Biogen Idec Q2 profit jumps, beats estimate  MyIris10 hours ago Biogen Idec Q2 Profit Surges, Lifts Full-Year View Yet Again  RTTNews.com6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less